跳至主要内容
临床试验/NCT01266395
NCT01266395已完成不适用

Impact of Morning Symptoms in Clinical Control of COPD

AstraZeneca1 个研究点 分布在 1 个国家目标入组 1,268 人开始时间: 2010年1月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
AstraZeneca
入组人数
1,268
试验地点
1
主要终点
Determine if there are differences in the impact of COPD on patients according to the characteristics of the disease. To measure the impact of specific self-administered questionnaires used in COPD: CDLMQ, GCSQ and CCQ

研究概览

简要总结

Observational study to know the Impact of morning symptoms in clinical control of COPD patients. 1200 patients will be included by General practitioners (GPs) and pneumologists. Objective: establish if there are differences in the impact of COPD on daily activities and morning symptoms measured through questionnaires of daily life activity (Capacity of Daily Living during the Morning (CDLM), Global Chest Symptoms Questionnaire (GCSQ))

研究设计

研究类型
Observational
时间视角
Cross Sectional

入排标准

年龄范围
40 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient has signed informed consent form
  • Patients of both sexes,> 40 years.
  • Patients diagnosed with COPD according to global consensus on the definition, classification and management of the disease (GOLD) criteria:
  • post-bronchodilator forced expiratory volume in 1 s (FEV1) / forced vital capacity (FVC) <70%
  • post-bronchodilator FEV1 <80% (stage II, III and IV)

排除标准

  • Participating in an epidemiological study or clinical trial
  • Patient with other respiratory disease than COPD (eg bronchial asthma, cystic fibrosis, severe bronchiectasis, restrictive lung disease, cancer, etc.).
  • Patients with mild COPD: FEV1> 80%

结局指标

主要结局

Determine if there are differences in the impact of COPD on patients according to the characteristics of the disease. To measure the impact of specific self-administered questionnaires used in COPD: CDLMQ, GCSQ and CCQ

时间窗: Retrospective, (previous 24 months)

Capacity of Daily Living during the Morning Qustionnaire (CDLMQ), Global Chest Symptoms Questionnaire (GCSQ)and COPD Control Questionnaire (CCQ)

次要结局

  • Assess comorbidities as a risk factor for frequent exacerbations(Retrospective, (previous 24 months))

研究者

发起方
AstraZeneca
申办方类型
Industry

研究点 (1)

Loading locations...

相似试验

Impact of Morning Symptoms in Clinical Control of... | 临床试验